SPM-0404

SPM-0404 is a novel, orally administered small molecule neurotherapeutic in preclinical development by Sea Pharmaceuticals. It acts as a potent and selective dual antagonist of the AMPA receptor and kainate receptor, both of which are subtypes of glutamate receptors involved in excitatory neurotransmission in the central nervous system. By inhibiting these receptors, SPM-0404 aims to modulate abnormal neuronal activity associated with neurological disorders. The drug has demonstrated robust anti-seizure efficacy in animal models and favorable pharmacokinetics with CNS penetration. Its primary indications under investigation include tinnitus, epilepsy, and amyotrophic lateral sclerosis (ALS), specifically sporadic ALS[1][2][3][5][8].

Other names

SEA4SEA-4SEA 4